AZD5305; HRRm; non-HRRm; mCSPC; Prostate Cancer
Showing 1 - 25 of >10,000
Metastatic Castration-Sensitive Prostate Cancer Trial in Worldwide (AZD5305, Placebo, Abiraterone Acetate)
Not yet recruiting
- Metastatic Castration-Sensitive Prostate Cancer
- AZD5305
- +4 more
-
Tucson, Arizona
- +192 more
Nov 6, 2023
Patterns and Associated Clinical Outcomes in Metastatic
Completed
- Metastatic Castration-resistant Prostates Cancer
-
Valledupar, Colombia
- +29 more
Jan 16, 2023
Learn About Novel Hormonal Therapies for Metastatic
Not yet recruiting
- Prostatic Neoplasms
- Novel hormonal therapy
-
New York, New YorkPfizer Inc
Nov 21, 2023
Learn About Novel Hormonal Therapies in People With Metastatic
Not yet recruiting
- Prostatic Neoplasms
- Novel hormonal therapy
-
New York, New YorkPfizer Inc
Oct 2, 2023
Metastatic Castrate-sensitive Prostate Cancer Trial in Germany, United States (Apalutamide, Androgen-deprivation Therapy (ADT))
Not yet recruiting
- Metastatic Castrate-sensitive Prostate Cancer
- Apalutamide
- Androgen-deprivation Therapy (ADT)
-
Lakewood, Colorado
- +5 more
May 23, 2023
Metastatic Triple Negative Breast Cancer Trial in Worldwide (Olaparib Continuous (28-Day cycle) 300 mg BD., Ceralasertib 160 mg
Active, not recruiting
- Metastatic Triple Negative Breast Cancer
- Olaparib Continuous (28-Day cycle) 300 mg BD.
- +2 more
-
Birmingham, Alabama
- +140 more
Nov 17, 2022
Metastatic Castrate Sensitive Prostate Cancer Trial in Worldwide (Niraparib, Abiraterone acetate (AA), Prednisone)
Recruiting
- Metastatic Castrate Sensitive Prostate Cancer
- Niraparib
- +3 more
-
Homewood, Alabama
- +439 more
Jan 17, 2023
Called AWARENESS Using Data From Alberta to Observe Treatment
Active, not recruiting
- Metastatic Castration-sensitive Prostate Cancer
- ADT (Eligard®*) with or without treatment intensification
-
Multiple Locations, Alberta, Canada
- +1 more
Aug 1, 2022
Determination of Prevalence and Features of HRRm mCRPC (ADAM)
Active, not recruiting
- HRRm mCRPC
-
Barnaul, Altai Krai, Russian Federation
- +12 more
Apr 26, 2022
Cancer Of Prostate, Prostate Tumors Trial run by the National Cancer Institute (NCI) (ADT, Prednisone, M7824)
Recruiting
- Cancer Of Prostate
- Prostate Neoplasms
- ADT
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jul 6, 2022
NSCLC NSCLC Trial in Worldwide (Durvalumab, Placebo for Olaparib, Olaparib)
Active, not recruiting
- Non-small Cell Lung Cancer NSCLC
- Durvalumab
- +7 more
-
Bonita Springs, Florida
- +67 more
Nov 15, 2022
Metastatic Prostate Cancer Trial (Darolutamide, Radium-223)
Not yet recruiting
- Metastatic Prostate Cancer
- (no location specified)
Mar 6, 2023
Endometrial Cancer, Gastric Cancer, Metastatic Castration-resistant Prostate Cancer Trial in Worldwide (Datopotamab deruxtecan
Not yet recruiting
- Endometrial Cancer
- +4 more
- Datopotamab deruxtecan (Dato-DXd)
- +8 more
-
Los Angeles, California
- +52 more
Aug 3, 2022
Prostate Cancer Trial in Boston (Precision screening intervention, Usual care)
Not yet recruiting
- Prostate Cancer
- Precision screening intervention
- Usual care
-
Boston, MassachusettsVA Boston Healthcare System Jamaica Plain Campus, Jamaica Plain,
Jun 21, 2023
Prostate Cancer Trial in Worldwide (talazoparib plus enzalutamide, Placebo plus enzalutamide)
Recruiting
- Prostate Cancer
- talazoparib plus enzalutamide
- Placebo plus enzalutamide
-
Birmingham, Alabama
- +306 more
Jan 18, 2023
HER2 Expression and Clinical Pathological Characteristics in
Recruiting
- HER2 Expression and Clinical Pathological Characteristics in Prostate Cancer
- Collect HER2 expression in prostate cancer patients
-
Jinan, Shandong, ChinaQilu hospital
Nov 17, 2023
Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8 Trial in Kansas City
Not yet recruiting
- Stage IIC Prostate Cancer AJCC v8
- +2 more
- Biospecimen Collection
- +9 more
-
Kansas City, KansasUniversity of Kansas Cancer Center
Nov 3, 2023
Prostate Cancer Trial in Cincinnati (Apalutamide Oral Product, Androgen Deprivation Therapy (ADT), Focal Therapy)
Not yet recruiting
- Prostate Cancer
- Apalutamide Oral Product
- +2 more
-
Cincinnati, OhioUniversity of Cincinnati Medical Center
Mar 27, 2023
Prostate Cancer Trial in Philadelphia (Daily adaptive SBRT with urethral sparing)
Not yet recruiting
- Prostate Cancer
- Daily adaptive SBRT with urethral sparing
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Mar 26, 2023